Anthos Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Anthos Therapeutics, Inc.
- Target Recruit Count
- 1900
- Registration Number
- NCT05712200
- Locations
- 🇧🇷
Anthos Investigative Site 1537, Rio De Janeiro, Brazil
🇧🇷Anthos Investigative Site 1510, Salvador, Brazil
🇧🇷Anthos Investigative Site 1521, Salvador, Brazil
Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Anthos Therapeutics, Inc.
- Target Recruit Count
- 705
- Registration Number
- NCT05421533
- Locations
- 🇬🇧
Anthos Investigate Site, Middlesex, United Kingdom
🇬🇧Anthos Investigative Site, Barry, Vale Of Glamorgan, United Kingdom
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
- Conditions
- Venous ThromboembolismDeep Venous ThrombosisPulmonary Embolism
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Anthos Therapeutics, Inc.
- Target Recruit Count
- 1020
- Registration Number
- NCT05171075
- Locations
- 🇨🇳
Southern Medical University - Zhujiang Hospital, Guangdong, China
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸Washington DC VAMC, Washington, District of Columbia, United States
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
- Conditions
- Deep Venous ThrombosisPulmonary EmbolismVenous Thromboembolism
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Anthos Therapeutics, Inc.
- Target Recruit Count
- 1655
- Registration Number
- NCT05171049
- Locations
- 🇮🇪
Bon Secour Hospital, Cork, Ireland
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸VA Connecticut Healthcare System, West Haven, Connecticut, United States
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
- Conditions
- Atrial Fibrillation (AF)Stroke
- Interventions
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Anthos Therapeutics, Inc.
- Target Recruit Count
- 1287
- Registration Number
- NCT04755283
- Locations
- 🇨🇳
Anthos Investigative Site, Tiachung, TXG, Taiwan
🇭🇺Anthos Investigative Site (4002), Nyíregyháza, SZ, Hungary
🇭🇺Anthos Investigative Site (4003), Nyíregyháza, SZ, Hungary
A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation
- Conditions
- Atrial Fibrillation
- Interventions
- Biological: MAA868 Cohort 1Other: PlaceboBiological: MAA868 Cohort 2Biological: MAA868 Cohort 3
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Anthos Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04213807
- Locations
- 🇺🇸
Anthos Investigative Site, McKinney, Texas, United States